Iovance Posts Record $122M Q3 Revenue, 60% Gross Margin; Reiterates $410-420M FY Guidance
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance reported record Q3 2026 product revenue of about $122 million, up roughly 80% year-over-year from $67 million and 22% sequentially from $99 million. U.S. Amtagvi sales drove the quarter at about $102 million, with global Proleukin adding about $20 million. Gross margin climbed to about 60% from 56% in Q2, and R&D spending fell about 16% sequentially, the fifth straight quarter of improvement. Net loss narrowed to $22.3 million, or $0.05 per share, from $91.3 million a year ago, and operating income was USD -23.968 million versus an IBES estimate of USD -40.8 million. Management reiterated full-year 2026 revenue guidance of $410-$420 million, the same range raised on September 29th, and said cash of about $382 million funds operations into 2029. The quarter confirms the commercial ramp is holding after the September guidance hike; the next hard data points are the UK and Swiss Amtagvi approval decisions expected in the first quarter of 2027.
At the time of this announcement, IOVA was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $1.76 to $15.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.